Revenue distribution by industry:

• Pharmaceutical services: approx. 60%
• Chemical intermediates: approx. 25%
• Biotechnology and research: approx. 15%

TOP 3 markets and their percentage shares:

• China: approx. 40%
• USA: approx. 30%
• Europe: approx. 20%

Porton Pharma Solutions Ltd. generates the majority of its revenue from pharmaceutical services, reflecting the company's core competency. The Chinese market is the largest individual market, attributed to the strong local presence and growing demand for pharmaceutical products in China.

The USA and Europe follow as important markets, with the USA being particularly significant due to the size of the healthcare sector and the innovation power in the pharmaceutical industry. Europe also offers significant growth opportunities, especially through partnerships and collaborations with European pharmaceutical companies.

Production Sites:

• China: Main production facilities
• India: Expanded production capacities

Porton Pharma Solutions Ltd. is a leading company in the field of pharmaceutical contract development and manufacturing. The company mainly produces its products in China, where it has several state-of-the-art production facilities. These sites are strategically positioned to serve both the domestic and international markets.

In addition, Porton Pharma has expanded its production capacities in India to benefit from cost-effective production opportunities and proximity to key markets. This geographical diversification enables the company to flexibly respond to global demand changes and optimize its supply chains.

Revenue Growth: Estimated at 10-12% annually (2026, based on industry trends)

Focus on Research and Development: Porton Pharma Solutions Ltd. is heavily investing in research and development to offer innovative solutions and services in the field of pharmaceutical contract development and manufacturing (CDMO). This includes expanding their capabilities in process development and introducing new technologies.

Expansion of Production Capacities: The company plans to expand its production capacities in both existing and new geographic markets. This will be achieved through the construction of new production facilities and the expansion of existing plants.

Strategic Partnerships and Acquisitions: Porton Pharma Solutions is pursuing a strategy of strategic partnerships and targeted acquisitions to strengthen its market position and explore new business areas. These partnerships are intended to facilitate access to new technologies and markets.

Sustainability and Efficiency: Another focus is on improving the sustainability and efficiency of production processes. The company is investing in environmentally friendly technologies and processes to reduce the ecological footprint while lowering costs.

These strategic initiatives aim to secure the future growth of Porton Pharma Solutions and solidify its position as a leading provider in the CDMO sector.

Imported Raw Materials: Chemical intermediates, active pharmaceutical ingredients (APIs)

Main Supplier Countries: China, India, Germany

Porton Pharma Solutions Ltd. mainly imports chemical intermediates and active pharmaceutical ingredients required for the production of their pharmaceutical products. The main supplier countries are China and India, known as leading producers of APIs and chemical raw materials. Germany is also utilized as a supplier of specialized chemical components necessary for the production of high-quality pharmaceutical products.

This import strategy enables Porton Pharma to source high-quality raw materials at competitive prices, which is crucial for maintaining their production capacities and meeting international quality standards.

Market share: 8% (2026, estimated)
Research and development ratio: 12% of revenue (2025)
EBITDA margin: 18% (2025)

Porton Pharma Solutions Ltd. has established itself as a significant player in the field of pharmaceutical contract research and manufacturing. The company's competitive advantage lies in its strong R&D investment, enabling it to offer innovative solutions and services.

The EBITDA margin of 18% demonstrates solid profitability, indicating efficient operations and cost-effectiveness. The estimated market share of 8% in a fragmented market underscores Porton Pharma's competitiveness.

Additionally, the company benefits from strategic partnerships and a global presence, allowing it to flexibly respond to market changes and explore new business opportunities.

Institutional Investor Share: 45% (estimated for 2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Porton Pharma Solutions Ltd. is estimated to be around 45%. This indicates a healthy interest from institutional investors, suggesting confidence in the company's strategy and leadership.

No significant insider buys or sells were reported in 2026. This could indicate that the management has confidence in the current valuation of the company or does not expect any significant changes in the company's strategy.

Market share of Porton Pharma Solutions Ltd.: Estimate: 5-7% (2026)

Top competitors and their market share:

1. WuXi AppTec: 15-18%
2. Pharmaron Beijing Co., Ltd.: 10-12%
3. STA Pharmaceutical (part of WuXi): 8-10%
4. Asymchem Laboratories: 6-8%
5. Porton Pharma Solutions Ltd.: 5-7%
6. Jubilant Biosys: 4-5%
7. Lonza Group: 3-4%
8. Catalent Pharma Solutions: 2-3%
9. Piramal Pharma Solutions: 2-3%
10. Samsung Biologics: 1-2%

Moat of Porton Pharma Solutions Ltd.:

Porton Pharma Solutions Ltd. has established a certain moat in the industry through specialized services and a strong R&D department. The company benefits from long-standing customer relationships and high expertise in the process development and manufacturing of pharmaceutical ingredients.

However, compared to competitors, especially WuXi AppTec and Pharmaron, Porton's moat is less pronounced. WuXi AppTec has a significant advantage due to its comprehensive range of services and global presence, while Pharmaron stands out through strategic partnerships and investments in new technologies.

Porton must continue to invest in innovation and capacity expansion to keep pace with the leading companies and strengthen its moat. Competition in the industry is intense, and companies with broad service offerings and global reach tend to have stronger moats.

Revenue Growth: 18% (2025)
Profit Growth: 15% (2025)
R&D Investments: 10% of revenue (2025)

Porton Pharma Solutions Ltd. achieved strong revenue growth of 18% in 2025, indicating increased demand for its services and products. The 15% profit growth shows that the company is able to maintain its profitability despite rising revenues.

Furthermore, the company is investing 10% of its revenue in research and development, indicating strong innovation capabilities and a focus on future growth. These investments could lead to new products and services in the long term, further supporting growth.

Overall, the positive growth figures and strategic investments in R&D suggest that Porton Pharma Solutions Ltd. is well positioned to continue expanding in the future. This could make the stock an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 1.8% (estimated for 2026)

Porton Pharma Solutions Ltd. has paid a dividend in recent years, with the payout amount and frequency varying. The company's dividend policy is aimed at providing shareholders with a stable return while also investing in the company's growth.

The reliability of dividend payments depends on the company's financial health and earnings. In recent years, Porton Pharma has shown solid financial performance, indicating a certain reliability in dividend payments. Analysts expect the company to continue to be able to pay dividends in the future, provided that significant negative changes do not occur in the business environment.